ClinicalTrials.gg
Drug

Bicalutamide clinical trials

Also written Casodex, ICI 176,334 and ICI 176334.

studies test it
94
open now
14
in phase 3
26
first study started
1994

How each study uses bicalutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the bicalutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Oct 1995 · CASODEX · NDA 020498 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Bicalutamide
61
Cosudex
5
Bicalutamide 50 mg
4
CDX
3
Cassotide
2

Brand

Casodex
36
Casodex 150mg
1

Development codes

ICI 176,334
9
ICI 176334
4

Studies by the year they started

93 studies that test it; most in 2001 (6)

Studies that test bicalutamide, by start year
YearStudies
19941
19953
19961
19981
19991
20004
20016
20023
20035
20044
20054
20065
20072
20081
20092
20105
20112
20121
20131
20141
20156
20164
20173
20182
20191
20204
20216
20221
20233
20243
20252
20265

Who runs them

Industry 22 · Other 72

AstraZeneca (13) · Memorial Sloan Kettering Cancer Center (5) · Radiation Therapy Oncology Group (5) · European Organisation for Research and Treatment of Cancer - EORTC (3) · CHU de Quebec-Universite Laval (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Mayo Clinic (3) · NRG Oncology (2)

Often tested with

Tested in the same studies.

Goserelin (16) · Leuprolide (14) · Flutamide (10) · Triptorelin (6) · Degarelix (5) · Ketoconazole (4) · Apalutamide (3) · Docetaxel (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Bicalutamide is the comparator. A study of two new drugs counts under both.

  • 1Apalutamide · Aragon Pharmaceuticals, Inc. · next primary completion Mar 2027
  • 1Rezvilutamide · Jiangsu HengRui Medicine Co., Ltd.
Reaching primary completion within a year · 10, 2 in phase 3

Studies that test bicalutamide, phase 3 first.

Studies

Open first, then newest update. How each study uses bicalutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 94

See all 94 studies that test bicalutamide →

Given beside what is tested · 57 — bicalutamide is usual care or a partner of the new treatment

Showing 20 of 57.

As the comparator · 15 — what is tested is compared with bicalutamide

Codes

What other systems call bicalutamide · ClinicalTrials.gg INT003346

  • MeSH (NLM) C053541bicalutamideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) A0Z3NAU9DPBICALUTAMIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 83008Confirmed FDA, Wikidata
  • Wikidata Q1988832bicalutamideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1599BicalutamideOne source FDA
  • DrugBank DB01128One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.